AR063259A1 - Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua - Google Patents
Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en aguaInfo
- Publication number
- AR063259A1 AR063259A1 ARP070104515A ARP070104515A AR063259A1 AR 063259 A1 AR063259 A1 AR 063259A1 AR P070104515 A ARP070104515 A AR P070104515A AR P070104515 A ARP070104515 A AR P070104515A AR 063259 A1 AR063259 A1 AR 063259A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapeutically effective
- dosage form
- ionic polymer
- microincluded
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formas solidas de dosificacion farmacéutica para su administracion oral que comprende una cantidad terapéuticamente efectiva de una forma cristalina inestable o una forma amorfa de un compuesto terapéuticamente efectivo microincluido en un polímero ionico insoluble en agua. Los compuestos terapéuticamente efectivos, que tienen tendencia a melificar, son microincluidos en una matriz de polímero ionico insoluble en agua para proporcionar una forma de dosificacion con un perfil de disolucion rápido, reproducible y completo. Estas nuevas formas solidas de dosificacion farmacéutica son utiles para el tratamiento o control de tina serie de enfermedades. Reivindicacion 2: La forma de dosificacion de acuerdo con la reivindicacion 1, en la que el compuesto terapéuticamente efectivo es un compuesto activador de la glucoquinasa. Reivindicacion 4: La forma de dosificacion de acuerdo con la reivindicacion 3, en la que el compuesto activador de la glucoquinasa es 2(R)-(3-cloro-4- metanosulfonil-fenil)-3-ciclo-pentil-N-(5-(1(S),2-dihidroxietil)-pirazin-2-il]-propionamida. Reivindicacion 11: La forma de dosificacion de acuerdo con la reivindicacion 10, en la que el polímero ionico insoluble en agua es un copolímero de ácido metacrílico y etilacrilato. Reivindicacion 15: La forma de dosificacion de acuerdo con las reivindicaciones de 1 a 13 para el tratamiento de la diabetes tipo 2. Reivindicacion 16: Un método para la preparacion de una forma solida de dosificacion farmacéutica para su administracion oral que comprende la microinclusion de una cantidad terapéuticamente efectiva de una forma cristalina inestable o una forma amorfa en un polímero ionico insoluble en agua, en la que la proporcion del compuesto terapéuticamente efectivo y el portador de polímero ionico es de 5:1 a 1:5, respectivamente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85185206P | 2006-10-13 | 2006-10-13 | |
US95440107P | 2007-08-07 | 2007-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063259A1 true AR063259A1 (es) | 2009-01-14 |
Family
ID=38857877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104515A AR063259A1 (es) | 2006-10-13 | 2007-10-11 | Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080107725A1 (es) |
EP (1) | EP2079447A1 (es) |
JP (1) | JP2010505901A (es) |
KR (1) | KR20090053858A (es) |
AR (1) | AR063259A1 (es) |
AU (1) | AU2007306402A1 (es) |
BR (1) | BRPI0719880A2 (es) |
CA (1) | CA2665604A1 (es) |
CL (1) | CL2007002921A1 (es) |
IL (1) | IL197871A0 (es) |
MX (1) | MX2009003516A (es) |
NO (1) | NO20091274L (es) |
PE (1) | PE20081461A1 (es) |
RU (1) | RU2009117711A (es) |
TW (1) | TW200824709A (es) |
WO (1) | WO2008043701A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
KR20140138725A (ko) * | 2012-02-16 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도 |
JO3339B1 (ar) * | 2012-09-11 | 2019-03-13 | Shanghai Inst Pharmaceutical Ind | شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه |
EP3228307A1 (en) * | 2016-04-05 | 2017-10-11 | Sandoz Ag | Solid dispersion comprising opioid antagonists |
EP3556354A4 (en) * | 2016-12-15 | 2020-07-01 | Hua Medicine (Shanghai) Ltd. | ORAL PRODUCTION OF A GLUCOKINASE ACTIVATOR AND PRODUCTION METHOD THEREFOR |
MX2020012965A (es) * | 2018-05-31 | 2021-02-16 | Hua Medicine Shanghai Ltd | Combinacion, composicion y preparacion de compuesto farmaceutico que comprende activador de glucocinasa e inhibidor de dpp-iv, metodo de preparacion y uso del mismo. |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
DE19515972A1 (de) * | 1995-05-02 | 1996-11-07 | Bayer Ag | Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung |
JP5170723B2 (ja) * | 1997-01-10 | 2013-03-27 | アボット・ラボラトリーズ | 活性薬剤の制御放出用錠剤 |
DE19732903A1 (de) * | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ES2248309T3 (es) * | 2000-05-03 | 2006-03-16 | F. Hoffmann-La Roche Ag | Activadores de glucoquinasa conteniendo hidantoina. |
JP5178982B2 (ja) * | 2000-05-18 | 2013-04-10 | セリックス, インコーポレイテッド | 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 |
CZ2004747A3 (cs) * | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Deriváty amidů jako GK aktivátory |
EP1496052B1 (en) * | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
US8501232B2 (en) * | 2002-04-23 | 2013-08-06 | Nanotherapeutics, Inc. | Process of forming and modifying particles and compositions produced thereby |
MY141521A (en) * | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
WO2005030257A2 (en) * | 2003-09-30 | 2005-04-07 | Solubest Ltd. | Water soluble nanoparticles inclusion complexes |
-
2007
- 2007-10-02 US US11/866,102 patent/US20080107725A1/en not_active Abandoned
- 2007-10-04 AU AU2007306402A patent/AU2007306402A1/en not_active Abandoned
- 2007-10-04 CA CA002665604A patent/CA2665604A1/en not_active Abandoned
- 2007-10-04 RU RU2009117711/15A patent/RU2009117711A/ru not_active Application Discontinuation
- 2007-10-04 EP EP07820919A patent/EP2079447A1/en not_active Withdrawn
- 2007-10-04 JP JP2009531811A patent/JP2010505901A/ja active Pending
- 2007-10-04 WO PCT/EP2007/060542 patent/WO2008043701A1/en active Application Filing
- 2007-10-04 KR KR1020097007378A patent/KR20090053858A/ko not_active Application Discontinuation
- 2007-10-04 MX MX2009003516A patent/MX2009003516A/es not_active Application Discontinuation
- 2007-10-04 BR BRPI0719880-9A2A patent/BRPI0719880A2/pt not_active IP Right Cessation
- 2007-10-09 TW TW096137876A patent/TW200824709A/zh unknown
- 2007-10-11 CL CL200702921A patent/CL2007002921A1/es unknown
- 2007-10-11 AR ARP070104515A patent/AR063259A1/es not_active Application Discontinuation
- 2007-10-12 PE PE2007001385A patent/PE20081461A1/es not_active Application Discontinuation
-
2009
- 2009-03-26 IL IL197871A patent/IL197871A0/en unknown
- 2009-03-27 NO NO20091274A patent/NO20091274L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2665604A1 (en) | 2008-04-17 |
US20080107725A1 (en) | 2008-05-08 |
CL2007002921A1 (es) | 2008-05-30 |
AU2007306402A1 (en) | 2008-04-17 |
JP2010505901A (ja) | 2010-02-25 |
TW200824709A (en) | 2008-06-16 |
BRPI0719880A2 (pt) | 2014-06-10 |
WO2008043701A1 (en) | 2008-04-17 |
PE20081461A1 (es) | 2008-10-18 |
EP2079447A1 (en) | 2009-07-22 |
IL197871A0 (en) | 2009-12-24 |
KR20090053858A (ko) | 2009-05-27 |
NO20091274L (no) | 2009-05-28 |
MX2009003516A (es) | 2009-04-14 |
RU2009117711A (ru) | 2010-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063259A1 (es) | Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua | |
EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
AR111679A2 (es) | Formulación farmacéutica de liberación controlada, procesos, usos, método | |
CY1118672T1 (el) | Συνθεσεις ταπενταδολης | |
BRPI0414254A (pt) | composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação | |
CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
AR052225A1 (es) | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones | |
EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
ECSP056076A (es) | Sistema de suministro para droga y terapia celular | |
MX2009004856A (es) | Matriz polimerica insoluble en agua para suministro de farmaco. | |
EA201190300A1 (ru) | Микроэлектрод и множественные микроэлектроды, содержащие устройства для высвобождения лекарственных средств в ткани | |
MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
BRPI0507683A8 (pt) | dose unitária de formulação farmacêutica com liberação controlada, seu processo de preparação e uso de um copolímero de poli(acrilato de etila, metacrilato de metila) neutro | |
BR112017026746A2 (pt) | composições de liberação de fármacos implantáveis e métodos de uso dos mesmos | |
AR086249A1 (es) | Composiciones de tabletas de disolucion rapida de administracion vaginal | |
AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
AR062721A1 (es) | Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla | |
AR051654A1 (es) | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones | |
DE60219314D1 (de) | Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
RU2016114098A (ru) | Новое производное аналога инсулина | |
AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
PE20081464A1 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
AR083693A1 (es) | Formulacion del inhibidor de proteina de transferencia del ester de colesterilo (inhibidor de la cetp), tableta, uso, proceso, kit | |
AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |